GET DAILY SIGNALSPDS Biotechnology (PDSB) Climbs +34% in 30 Days on Financing and Clinical Updates
Key Takeaways
- PDS Biotechnology (PDSB) has climbed roughly +34% over the trailing 30 days, advancing from about $0.80 to near $1.07 on elevated trading volume.
- The rally has been driven by a strategic refocus on lead asset PDS0301 and a new equity financing led by Dr. Patrick Soon-Shiong's Nant Capital.
- Over the trailing quarter, shares are up roughly +54%, a sharp recovery from a mid-August low below $0.26.
- Key catalysts include the up-to-$22.55 million PIPE financing and publication of VERSATILE-002 Phase 2 data in JAMA Oncology.
- The stock remains highly volatile and pre-revenue, with meaningful dilution and funding risks typical of a clinical-stage biotechnology company.
- For additional detail on valuation and expectations, explore the company's Price Targets, Earnings, and Forecast pages.
- Readers can also explore Trending AI Robots for automated trading strategies tied to this and other tickers.
Company Background and Strategic Focus
PDSB is a clinical-stage immunotherapy company based in Princeton, New Jersey, that develops targeted treatments for cancer. Its lead program, PDS0301, is an investigational tumor-targeted interleukin-12 immunocytokine intended to boost anti-tumor immune responses while reducing systemic side effects. The firm also holds the Versamune platform, which includes PDS0101 for HPV16-positive cancers. As a pre-revenue company, it relies on equity and debt financing to support operations, and investors track clinical readouts and funding events closely because these can produce significant price moves.
Stock Performance Over the Past 30 Days and Quarter
In the trailing 30 days, PDSB advanced approximately +34%, moving from a late-September close near $0.80 to roughly $1.07 in late October 2026. Volume has run well above historical norms, and single-day swings have been frequent. Over the full quarter the gains are larger still, with shares rising about +54% from a late-July close around $0.69. The path was not straight: the stock dropped sharply in early-to-mid August before rebounding strongly from late August onward, touching an intraday high above $1.70 in mid-October before easing back.
Drivers Behind the Recent 30-Day Advance
Two main developments fueled the move. In early September the company announced a private investment in public equity of up to $22.55 million led by Nant Capital, with participation from existing shareholders. The deal included an initial close of about $11.55 million and a potential milestone tranche tied to submission of a registrational Phase 3 protocol for PDS0301. Dr. Patrick Soon-Shiong joined the board as part of the financing. Also in September, VERSATILE-002 Phase 2 results for PDS0101 plus pembrolizumab in HPV16-positive head and neck cancer appeared in JAMA Oncology, renewing attention to the platform. I checked comparable setups using Tickeron’s AI Screener to see how the stock stacks up against peers in the sector.
Broader Factors Behind the Quarterly Rebound
The quarterly recovery reflects a broader corporate reset. In early August, PDSB announced a strategic emphasis on PDS0301 along with a workforce reduction of roughly 36%. Shareholders approved an increase in authorized shares, and the company reported a wider-than-expected second-quarter loss. The CFO departed in mid-September, with the CEO assuming interim financial duties. The Nant Capital financing later eased near-term funding worries and brought external validation for PDS0301 in hard-to-treat tumors such as metastatic colorectal and prostate cancers. Heavy short covering and speculative interest added to the rebound from the August low.
Key Items to Watch Going Forward
Investors will focus on progress toward a Phase 3 protocol submission for PDS0301, which also triggers the contingent financing close, plus further data from NCI-led programs in colorectal and prostate cancer. Developments in the VERSATILE-003 trial for PDS0101 and any partnering activity remain relevant. On the financial side, cash runway, dilution from warrants and the at-the-market program, and operating expenses will stay in view. Sector sentiment and macroeconomic conditions can also affect small-cap biotech names. Trial results and regulatory decisions carry substantial uncertainty, as is typical for clinical-stage companies.
Using Tickeron Tools in My Research
I often review Tickeron’s AI Trading Bots when evaluating volatile names like this one. The platform surfaces top-performing automated strategies across thousands of tickers, letting me compare different timeframes and risk profiles side by side. It offers a useful quantitative lens without replacing fundamental analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
PDSB in +35.30% Uptrend, advancing for three consecutive days on October 21, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where PDSB advanced for three days, in 192 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Aroon Indicator entered an Uptrend today. In 82 of 107 cases where PDSB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.
Bearish Trend Analysis
The 10-day RSI Indicator for PDSB moved out of overbought territory on October 14, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 20 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Momentum Indicator moved below the 0 level on October 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PDSB as a result. In 70 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for PDSB turned negative on October 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 45 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PDSB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
PDSB broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-21.562) is normal, around the industry mean (3.037). P/E Ratio (-1.664) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. PDSB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 88 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PDSB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of clinical-stage immunotherapies to treat various early-stage and late-stage cancers which includes head & neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer and related cancers
Industry Biotechnology
Advertisement